Please login to the form below

Not currently logged in
Email:
Password:

Celgene engages IBM Watson for patient safety work

Aims to improve its pharmacovigilance methods with a new cloud-based platform
Celgene

Celgene has teamed up with IBM Watson Health to improve its existing pharmacovigilance methods through the creation of a new cloud-based drug evaluation platform.

Built using the Watson Health Cloud supercomputer, the new system will collect patient data to assess, monitor and report adverse drug reactions.

IBM says the high volumes of data will be obtained from “diverse sources, including anonymised electronic medical records, medical claims databases and other healthcare information sources”.

'Watson for Patient Safety' aims to aid life sciences companies in managing and interpreting Individual Case Safety Reports (ICSRs), using its trademark cognitive computing technology to increasingly identify potential drug safety signals.

The partners hope this will reduce the time and monetary drain of failed late-stage clinical trials for drug developers through access to such comprehensive outcome- and evidence-based profiling, ultimately getting drugs to market faster.

John Freeman, Celgene's corporate vice president of global drug safety and risk management, said: “With this collaboration, we intend to create a paradigm shift in identifying patient safety data that we hope can be applied across the entire product lifecycle - from early development to approved medicines.

“The new offering we are co-developing will bring the cognitive computing power of Watson and its growing view of clinical, research and social health data to bear on this critical healthcare challenge.”

Due to be developed across several phases, the first module of 'Watson for Patient Safety' is expected to be ready within the next year.

Article by
Rebecca Clifford

3rd November 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics